Published online Nov 26, 2023. doi: 10.12998/wjcc.v11.i33.7987
Peer-review started: August 28, 2023
First decision: November 1, 2023
Revised: November 6, 2023
Accepted: November 17, 2023
Article in press: November 17, 2023
Published online: November 26, 2023
Processing time: 88 Days and 8 Hours
We believe these findings can reassure patients regarding new onset or worsening urinary symptoms in the setting of long coronavirus disease (COVID). Although, additional research needs to be performed to further investigate the impact of COVID-19 on urological health.
To our knowledge this is the first study to report long term follow up of patients with COVID-associated cystitis (CAC). Our results suggest a promising prognosis of these patients when managed conservatively.
Of the 350 participants included in this study, 310 patients (87%) reported improvement in their urinary symptoms at 21-28 mo following their COVID-19 hospitalization discharge. Of those, the patients with new onset CAC symptoms displayed a decrease of 9-10 points in the overactive bladder (OAB) and quality of life scores and 95.4% of these patients reported symptom improvement at follow-up. On the other hand, patients who previously experienced symptoms of OAB had a score decrease of 6 points and 60.7% of these patients had symptomatic improvement at follow-up.
We prospectively evaluated a cohort of 350 patients who were previously hospitalized for COVID-19 between May and December 2020. These patients were included in the study if they displayed any CAC symptoms following their hospital discharge. Patients were evaluated using surveys that assessed their urinary symptoms as well as their quality of life at two time points; 10-14 wk following discharge and 21-28 wk following discharge. Their symptoms were managed using conservative measures such as behavior modification and standard OAB medications.
We aimed to evaluate a cohort of 350 patients for new or worsening OAB symptoms using OAB survey based results 21-28 mo following their COVID-19 hospitalization.
There have been early observational studies that suggest COVID-19 can manifest as urologic symptoms including urinary frequency, urgency, and nocturia which has been CAC. We recently described the results of OAB on a cohort of 350 patients who report new or worsening OAB symptoms 10-14 wk following their COVID-19 hospitalization, but there is little known regarding the management and long-term outcomes of CAC.
COVID-19 is an infection caused by the SARS-CoV-2 virus that has caused over 100 million cases and over 1 millions deaths in the United States since its identification in late 2019. There are many symptoms attributed to COVID-19 and multiple organ systems are known to be impacted including urologic manifestations. Little is known regarding long term manifestations and the impact of COVID-19 on the urologic system.